LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Suletud

SektorTervishoid

1.62 -2.99

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.58

Max

1.69

Põhinäitajad
By Trading Economics
Sissetulek	-2.8M -16M
Müük	-8.7M 5.5M
Kasumimarginaal	-282.723
Töötajad	81
EBITDA	-4.2M -15M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+127.98% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. mai 2026

Turustatistika
By TradingEconomics
Turukapital	43M 695M
Eelmine avamishind	4.61
Eelmine sulgemishind	1.62

Uudiste sentiment

By Acuity

50%

164 / 349 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. märts 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Iran Peace Talks -- Market Talk

26. märts 2026, 23:36 UTC

Market Talk

Uudisväärsed sündmused

Gold Rises Amid Signs of Easing Middle East Tensions -- Market Talk

26. märts 2026, 23:35 UTC

Omandamised, ülevõtmised, äriostud

Pernod Ricard: Confirms Discussions With Brown-Forman

26. märts 2026, 23:29 UTC

Tulu

Haier Smart Home: Company to Finance Share Buybacks Via Internal Funds >600690.SH

26. märts 2026, 23:28 UTC

Tulu

Haier Smart Home Plans A Share Buybacks of CNY3.0B-CNY6.0B >600690.SH

26. märts 2026, 23:28 UTC

Tulu

Haier Smart Home Plans to Increase Payout Ratio to 60% for 2027, 2028 >600690.SH

26. märts 2026, 23:28 UTC

Tulu

Haier Smart Home Plans Cash Dividend Payout Ratio of Up to 58% for 2026 >600690.SH

26. märts 2026, 23:27 UTC

Tulu

Haier Smart Home 2025 Net CNY19.55B Vs. Net CNY18.73B >600690.SH

26. märts 2026, 23:27 UTC

Tulu

Haier Smart Home 2025 Rev CNY302.33B Vs. CNY286.01B >600690.SH

26. märts 2026, 23:08 UTC

Market Talk

Infratil's Investor Day Addresses Data-Center Issues -- Market Talk

26. märts 2026, 23:04 UTC

Omandamised, ülevõtmised, äriostud

Pernod Ricard in Talks to Combine With Jack Daniel's Maker Brown-Forman -- WSJ

26. märts 2026, 23:04 UTC

Omandamised, ülevõtmised, äriostud

Families Behind Pernod, Brown-Forman Would Each Likely Retain Significant Stakes, Source Says -- WSJ

26. märts 2026, 23:04 UTC

Omandamised, ülevõtmised, äriostud

Pernod, Brown-Forman Discussing Mostly Stock Deal, Source Says -- WSJ

26. märts 2026, 23:04 UTC

Omandamised, ülevõtmised, äriostud

Pernod-Brown-Forman Deal Announcement Could Be Weeks Away, Sources Say -- WSJ

26. märts 2026, 23:04 UTC

Omandamised, ülevõtmised, äriostud

Pernod in Deal Talks With Brown-Forman -- WSJ

26. märts 2026, 22:41 UTC

Omandamised, ülevõtmised, äriostud

Brown-Forman: No Agreement Has Been Reached as to Terms of Any Possible Pernod Ricard Transaction

26. märts 2026, 22:41 UTC

Omandamised, ülevõtmised, äriostud

Brown-Forman: Synergies From Contemplated Pernod Ricard Combination Expected to Be Significant

26. märts 2026, 22:26 UTC

Tulu

Jiangxi Copper 2025 Rev CNY544.62B Vs. CNY516.61B >0358.HK

26. märts 2026, 22:26 UTC

Tulu

Jiangxi Copper 2025 Net CNY7.13B Vs. Net CNY6.96B >0358.HK

26. märts 2026, 22:26 UTC

Tulu

Jiangxi Copper Higher Demand For Products Supported Results>0358.HK

26. märts 2026, 22:08 UTC

Tulu

Air China 2025 Loss CNY1.79B Vs. Loss CNY232.56M >0753.HK

26. märts 2026, 22:08 UTC

Tulu

Air China Impairment Loss on Goodwill Weighed on Results>0753.HK

26. märts 2026, 22:08 UTC

Tulu

Air China 2025 Rev CNY171.48B Vs. CNY166.70B >0753.HK

26. märts 2026, 22:07 UTC

Market Talk

Uudisväärsed sündmused

Global Energy Roundup: Market Talk

26. märts 2026, 22:07 UTC

Market Talk

Uudisväärsed sündmused

Open-Pit Gold Miners Most Exposed to High Fuel Prices -- Market Talk

26. märts 2026, 22:00 UTC

Tulu

Tsingtao Brewery 2025 Net CNY4.59B Vs. Net CNY4.34B >0168.HK

26. märts 2026, 22:00 UTC

Tulu

Tsingtao Brewery: Higher Volume Sales of Beer Supported Results>0168.HK

26. märts 2026, 22:00 UTC

Tulu

Tsingtao Brewery 2025 Rev CNY32.47B Vs. CNY32.14B >0168.HK

26. märts 2026, 21:39 UTC

Omandamised, ülevõtmised, äriostud

BlueScope: Sees Early Indications of Strong Interest in Site Adjacent Western Port

26. märts 2026, 21:38 UTC

Omandamised, ülevõtmised, äriostud

BlueScope: Has Begun Expression of Interest Process For 65-Hectare Site Adjacent Western Port

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

127.98% tõus

12 kuu keskmine prognoos

Keskmine 3.83 USD 127.98%

Kõrge 6 USD

Madal 1 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

164 / 349 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.